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Abstract
Re-emergence and geographic expansion of leishmaniasis is accelerating efforts to develop a safe and 
effective Leshmania vaccine. Vaccines using Leishmania recombinant antigens, such as LiHyp1, which 
is mostly present in the amastigote parasite form, are being developed as a next generation to crude 
killed parasite-based vaccines. The main objective of this work was to develop a LiHyp1-based vaccine 
and determine if it can induce protective immunity in BALB/c mice when administered using a dissolvable 
microneedle (DMN) patch by the skin route. The LiHyp1 antigen was incorporated into cationic liposomes 
(CL), with or without the TLR9 agonist, CpG. The LiHyp1-liposomal vaccines were characterized with 
respect to size, protein encapsulation rates and retention of their physical characteristics after 
incorporation into the DMN patch. DMN mechanical strength and skin penetration ability were tested. A 
vaccine composed of LiHyp1, CpG and liposomes and subcutaneously injected or a vaccine containing 
antigen and CpG in DMN patches, without liposomes, induced high  antibody responses and significant 
levels of protection against L. donovani parasite infection. This study progresses the development of an 
efficacious leishmania vaccine by detailing promising vaccine formulations and skin delivery technologies 
and it addresses protective efficacy of a liposome-based dissolvable microneedle patch vaccine system. 
1. Introduction 
Leishmaniases, caused by Leishmania protozoa, are vector-borne diseases that globally affects up to 2 
million people per annum. Visceral leishmaniasis, caused mainly by L. infantum or L. donovani species, 
is fatal in up to 95% of cases if left untreated. Current drug regimens suffer from low efficacy, long 
duration of treatment, toxicity, parasite resistance and cost (Uliana et al., 2018). The fact that 
individuals who are cured from leishmaniasis develop lifelong immunity against subsequent parasite 
infections supports the concept of disease prevention through prophylactic vaccination. Advances in 
understanding the infection pathogenesis and the generation of host-protective immunity, together with 
the parasite’s genome sequencing, has opened new perspectives for vaccine development. However 
few candidate vaccines have progressed to the clinic (Duarte et al., 2016), there is still a lack of a 
licensed vaccine to prevent all kinds of human leishmaniasis, similar to many other tropical and 
neglected infectious diseases (Gillespie et al., 2016). Since the first-generation experimental vaccines 
against leishmaniasis (i.e. killed whole Leishmania parasites) (Noazin et al., 2008) significant advances 
in this field have been achieved, such as the development of recombinant antigen-based vaccines 
against canine leishmaniasis (Fernandez Cotrina et al., 2018; Martin et al., 2014; Toepp et al., 2018). 
Leishmania parasites replicate in amastigote form into host macrophages, expressing amastigote-
specific proteins to cause and maintain disease. In this context Leishmania amastigote-specific 
antigens are preferred over promastigote ones (Fernandes et al., 2012; Martins et al., 2013). One 
amastigote-specific antigen that demonstrates promise is LiHyp1 (XP_001468941.1), a 36.6kDa 
antigen first identified in an extract of axenic L. infantum amastigotes by immunoproteomic approaches 
(Coelho et al., 2012; Duarte et al., 2016; Fernandes et al., 2012). It belongs to the superfamily of 2-
oxoglutarate-dependent and iron-dependent oxygenases and its alkylated DNA repair function is 
considered to be essential for amastigote survival (Coelho et al., 2012; Duarte et al., 2016).  Soluble 
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subunit proteins generally require an immune modulating adjuvant to induce a protective immune 
response. Among them, liposomes have been widely studied due to their biocompatibility, ability to 
incorporate a range of compounds and versatility related to size and composition (Li et al., 2019). Due 
to their characteristic of being easily recognized and taken up by antigen-presenting cells (APCs), 
liposomes act as a carrier and delivery system for the encapsulated antigen and immunomodulator, 
resulting in immunoadjuvant action (De Serrano and Burkhart, 2017; Frezard, 1999). Cationic 
liposomes (CL) have been used as a vaccine platform against infectious diseases`, including those 
caused by intracellular pathogens. Their key advantages include the high encapsulation efficiency of 
negatively-charged antigen and immunomodulator and the enhanced uptake by APCs due to strong 
electrostatic interactions with the cell surface`, associated to induction of specific Th1 and Th17 
mediated immune responses 5 (Christensen et al., 2011; Schwendener, 2014). The use of CL 
adsorbed with unmethylated cytosine-phosphate-guanine oligodeoxynucleotides (CpGs) often shows 
an improvement in the magnitude of the humoral and Th1-polarized immune response to the  co-
encapsulated antigen, sometimes shifting the IgG1/IgG2a balance towards a predominant IgG2a 
response, increasing the antigen-specific release of interferon γ (IFNγ) by CD8+ T cells and favoring 
protection from Leishmania subsequent infection (Bal et al., 2011; Bhowmick et al., 2008; Heravi 
Shargh et al., 2012).
 Currently, vaccines are administrated mostly by parenteral routes, requiring injection of the liquid 
vaccine.  This presents issues with respect to the requirement of needles, syringes and biohazardous 
sharps waste as well as the requirement for cold chain to prevent vaccine degradation (Kristensen et 
al., 2016). The skin plays an important and vital role in the pathogen host defense and it contains a high 
density of dendritic cells. Thus, the skin route of administration has great potential for minimally invasive 
application of vaccines (Fehres et al., 2013). Microneedle-based delivery systems (MN) consist of 
micron-sized needles that penetrate skin in a minimally invasive manner allowing application of a broad 
range of drugs and vaccines  (Marshall et al., 2016). One class of MN that has been highlighted for its 
advantages in vaccine application is the dissolvable microneedles (DMN) (Donadei et al., 2019; 
Marshall et al., 2016; McGrath et al., 2014; Vrdoljak et al., 2016). These arrays contain the active 
molecules incorporated into a biodegradable matrix, capable of piercing through the stratum corneum, 
and then dissolving once placed in the skin, thereby releasing their content. The interest in dissolvable 
microneedle technology for vaccines has increased in the recent past, mainly due to the development 
of new, production techniques, which have advantages over some other platforms, such as lack of 
waste of active material, ease of incorporation of a full dose, enhanced stability of the vaccine and  
biodegradation of delivery system (Donadei et al., 2019; Marshall et al., 2016; McGrath et al., 2014; 
Vrdoljak et al., 2016). In addition to safety, an ideal leishmania vaccine should be effective against 
different Leishmania species and should be stable outside of cold chain. Creating a solid dosage form 
generally results in a more stable vaccine format compared to liquid (Vrdoljak et al., 2016), thereby 
potentially decreasing vaccine wastage and costs (Duttagupta et al., 2017).
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The overall objective of this work was to determine if the amastigote antigen, LiHyp1, induces protective 
immunity when delivered in a cationic liposome and stabilized and delivered in a DMN patch. We 
examined the biophysical parameters of a cationic liposome containing the antigen with or without the 
TLR9 adjuvant CpG. We also characterized physical parameters of the DMN patch containing antigen 
encapsulated in liposomes and/or formulated with CpG and the effect of DMN incorporation on the 
liposome. Finally, we determined the immunogenicity and efficacy of vaccines incorporated into DMN 
patches, compared to a positive control, liquid vaccine, containing both CpG and liposomes, which was 
injected subcutaneously, in murine model of visceral leishmaniasis caused by L. donovani. To our 
knowledge, this is the first study that examines the protective efficacy of a liposome-based dissolvable 
microneedle patch vaccine system. 
2. Material and Methods
2.1 Materials 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, >99%) and 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP, chloride salt, >99%) were purchased from Avanti Polar® (Alabama, US). Bovine 
serum albumin (BSA), Polycarbonate 0.2µm and 0.1µm-pore membranes, poly(vinyl-alcohol) (PVA), 
cholesterol (CHOL), chloroform, trehalose, Phosphate Buffered Saline (PBS - pH 7.4), isopropyl-β-D-
thiogalactopyranoside (IPTG), Imidazole ACS reagent grade (99%), Urea reagent grade (98%), 4-
Chloro-1-naphthol solution,  3,3′-Diaminobenzidine (DAB) and phosphotungstic Acid (PTA) were 
purchased from Sigma Aldrich (St. Louis, Missouri, USA). Tissue-Plus™ O.C.T Compound, ShandonTM 
Blue Tissue Marker Dye, NuPAGE® Bis-Tris Precast Gels, Slide-A-Lyzer™ Dialysis Cassettes 7.5K 
were obtained from Thermo Fisher Scientific Inc. (Massachusetts, USA). 3M® SCOTCH (TM) #810 
double-sided tape was used to de-mould the patches. Trichome Masson’s stain kit from CellPath 
(Wales, UK) was used in the histopathology studies. Formvar/carbon coated grids (Cu-300CN; Pacific 
Grid-Tech, San Francisco, CA) were used in the transmission electron microscopy experiments. Human 
/ mouse CpG-C oligodeoxynucleotide (ODN2395) (Hycult Biotech) was purchased from Cambridge 
Bioscience (UK) and used as TLR9 immunoadjuvant. 
2.2  Expression, purification and physical characterization of recombinant LiHyp1
The plasmid vector pET21aLiHyp1, expressing recombinant LiHyp1 - (XP_001468941.1), a protein 
member of super-oxygenase family in Leishmania amastigotes, was kindly provided by Professor 
Eduardo Coelho (Sector of Clinical Pathology, Technical College - Coltec, UFMG, Brazil). This plasmid 
was constructed from the commercial plasmid pET21a (Novagen) with fragment of exogenous DNA 
obtained from Leishmania infantum and related to the gene encoding LiHyp1 (Martins et al., 2013). The 
plasmid vector was transformed into Escherichia coli (C41 strain), colonies were checked for cloning 
confirmation, selected, expanded in LB culture media supplemented with Ampicillin 100 μg/mL and, 
stimulated with 1mM of expression inducer IPTG for 3 hrs at 37°C, 180rpm stirring. The bacteria were 
pelleted, lysed in PBS containing 8M urea and 40mM imidazole and treated for purification by nickel 
affinity chromatography HisTrap™ HP coupled to FPLC (GE Healthcare Life Sciences) as previously 
described (Martins et al., 2013). The purified His-tag rLiHyp1 protein solution was dialyzed in PBS 4M 
urea, treated for LPS elimination (EndoTrap® red Endotoxin Removal Kit) according to manufacturer’s 
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specification, and quantified using the Lowry method, modified by Peterson (Peterson, 1977)  and 
confirmed by absorption spectrometry at 280 nm. This antigen preparation was used for liposome 
preparation or aliquoted and freeze-dried. The procedure is schematized in Fig. 1A. Western Blot using 
anti-His monoclonal antibody (GE Healthcare life Sciences, diluted 1:3000 in blocking buffer) was used 
to confirm rLiHyp1 constitutive expression and purity . Antibody binding was detected with peroxidase-
coupled anti-mouse IgG (HRP) (Millipore, Temecula, California, USA, diluted 1:5000). After further 
washing, the recombinant antigen (rAg) was revealed by the reaction of Chloronaphthol and DAB with 
30% H2O2.
2.3 Preparation and characterization of cationic liposome (CL) formulations of antigen
Cationic liposomes (CL) were made from lipids DPPC, CHOL and DOTAP at 6:2.4:3 molar ratio. 
Antigen was encapsulated in liposomes using a dehydration–rehydration technique (Zadi and 
Gregoriadis, 2000). Briefly, a suspension of liposomes was first obtained at 50 g/L lipid, through 
hydration of the lipid film with deionized water, submission to freeze and thaw cycles and then repeated 
extrusions (5 cycles) across 0.2 µm and 0.1 µm pore polycarbonate membranes (Nayar et al., 1989). 
The resulting empty unilamellar liposomes suspension was then mixed with the compounds to be 
encapsulated (bovine serum albumin, BSA or LiHyp1 protein at 20 g per mole of lipid; CpG ODN at 1.8 
g per g of protein). Trehalose was added as cryoprotectant (at 3:1 sugar/lipid mass ratio and the 
mixture was immediately lyophilized (freeze-dryer L101; Liotop, São Carlos/SP, Brazil). and stored at -
20oC until use. For liposome reconstitution, ultrapure water was added to freeze-dried samples at a 
final trehalose concentration of 15% (w/v) and suspensions were incubated for 30 min at 45oC with 
intermittent vortexing. The liposome formulations intended for subcutaneous immunization were diluted 
at 100 μg/mL of protein with PBS and then submitted to dialysis (7.5K – Slide-A-Lyzer™ Dialysis 
Cassettes) against PBS containing 0.8M urea. Liposome samples intended for incorporation into DMN 
patches were dialyzed against a solution of trehalose 15% (w/v) and PVA 1.25% (w/v) containing 0.8 M 
urea. The particle size distribution and zeta-potential were first evaluated by dynamic light scattering 
(DLS) , using a Malvern’s Zetasizer Nano ZS instrument (Malvern Instruments, Worcestershire, UK) 
with the detector at 173° angle and 100.000 counts/s. Electrophoretic mobility of samples was 
converted in Zeta potential (ζ, mV) by Malvern Panalytical Software v3.30 using Smoluchowski 
equation. In the case of polydisperse samples with polydispersity index (PDI) higher than 0.3, particle 
size was further assessed by Nanoparticle Tracking Analysis, (NTA®) version 3.0 0064 (NANOSIGHT, 
Malvern Instruments, UK) (Filipe et al., 2010).  For the analysis, NTA 3.2 Dev Build 3.2.16 program was 
used, with the following image capture configurations: 5 threshold, 15 Gain, Automatic Luminosity and 
Blur. Measurements were carried out at 25°C and at the day of liposomes resuspension and repeated 
at least three times for each sample. Protein encapsulation efficiency into liposomes was determined by 
quantification of free and encapsulated protein, in PBS reconstituted DMN or liquid samples, using the 
Lowry method (Peterson, 1977). LiHyp1-liposomes were separated from free protein by centrifugation 
at 20,000 x g for 15 min at 4°C. and washing 3 times with PBS. Protein content in all washes was 
determined. Protein encapsulation rate was determined according to the following formula:
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𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 (%) =  
𝐴𝑚𝑜𝑢𝑛𝑡 (µ𝑔) 𝑜𝑓 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 (µ𝑔) 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑖𝑛 𝑡ℎ𝑒 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛
2.4 Liposome-containing DMN patches
2.4.1 Production of liposome-containing dissolvable microneedle patches.
DMN patches contained 25 microneedles in a 1-cm2 area (Fig. 2B). Each microneedle was 500 m in 
height and had a 3:2 height : base ratio (O'Mahony, 2014). Patches were prepared as previously 
described (Vrdoljak et al., 2016). Briefly, formulation was delivered directly onto water-filled microneedle 
cavities in a polydimethylsiloxane (PDMS) mould at a rate of 8 μl/min. Formulation in the moulds was 
dried overnight at 25°C and 10 mBar of pressure and then pulled from the mould onto medical grade 
adhesive tape (1525 L-Poly-Med tape, 3 M) (Donadei et al., 2019; Vrdoljak et al., 2016).
2.4.2 Characterization of antigen and liposomes in DMN patches 
Lack of degradation of rLiHyp1 in DMN patches was determined by dissolving patches in PBS and 
assessing its migration by 12% SDS-PAGE, using NuPAGE® Bis-Tris Precast Gels (Thermo Fisher 
Scientific Inc., Massachussetts, USA) according with the manufacturer protocols. To assess the 
morphology and size integrity of the liposomes after incorporation into DMN, patches were completely 
dissolved into 1 mL of PBS and samples were submitted to Electron Transmission Microscopy and 
NTA. Samples were applied onto the formvar/carbon coated grids by drop to drop method and 
subsequently negative stained with PTA at 1%. Ten l of liposomes (dilution 50X) in PBS were dropped 
onto the grid and allowed to adsorb for around 1 min. The surplus was removed by filter paper 
(Whatman #44) and the grids were washed three times in deionized water droplets and then, immersed 
in a staining (PTA 1%) droplet, blot in a filter paper, and let air dry overnight. Samples were analyzed 
using a Jeol 2000FXII Transmission Electron Microscope (TEM) operating at an acceleration voltage of 
80KV, line resolution of 0.34 nm, point resolution of 0.49nm, and Cs of 6.3 (spherical aberration), 
implying high contrast (model Tecnai G2 Spirit, 2006; FEI).  Representative electron micrographs were 
taken at magnifications of X80.000 to X200.000. The particles size was assessed by TEM and 
compared with the results obtained by NTA. Based on the 8-μL volume of formulation per patch, the 
amount of protein per patch could be estimated as 5 μg.
2.4.3 Visual assessment and Score of DMN patches
DMN were visually evaluated using an Olympus BX51 optical microscope. DMN images were recorded 
with an Olympus DP70 digital camera (Olympus, USA), coupled above objective microscope lenses 
with 400X magnification. A scoring system was used to grade the physical quality of 1 cm2 patch units; 
a patch with a score of 100 reflected a patch where all 25 microneedles per 1cm2 were perfectly formed 
(Table 1). A value of 88 was given for the lower level of specification (LSL) based on historical 
qualitative results (>22 perfect MN per patch consisting of perfect 8-sided DMN) (Table 1). In order to 
closely analyze the DMN texture, their surface was imaged by scanning electron microscopy (SEM), 
using a JEOL JSM 5800 (JEOL USA Inc, Peabody, MA, USA) at 3 kV microscope equipped with an 
ISIS EDS 300 analyzer. Samples without any treatment were fixed with a double-sided adhesive tape in 
a metal support and subjected to vacuum for analysis.
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2.4.4 Mechanical Properties of Liposome DMN patches
Mechanical properties of the microneedles, specifically the pressure required to cause compression or 
breakage of the DMN, were assessed using a TA.XT-plus Texture Analyser (Stable Micro Systems, 
Surrey, UK) by application of a known axial compression load to DMN structures. DMN patches were 
attached to a cylindrical probe (length 3.5 cm, cross-sectional area 1.5 cm2) using double-sided 
adhesive tape (3M) and pressed against a flat block of aluminum of dimensions 9.2×5.2 cm at a rate 
0.5 mm/s until complete compression. Pre-test and post-test speeds were 1mm/s while the trigger force 
was set at 0.049 N. Test conditions included application of an increasing axial load until a probe 
displacement of 0.5 mm occurred or application of known force with measurement of probe 
displacement. Three samples from each batch (score ≥92) were evaluated. Measurements were carried 
at room temperature and humidity. The results are expressed as the maximum pressure (force, per unit 
of cross section area) (N/m2) that the DMN material withstood before it compressed. Sudden breakage 
of microneedles was not observed. 
2.5 Skin insertion studies
Porcine skin was used as a model for in vitro DMN skin penetration studies, as previously described 
(McGrath et al., 2014; Vrdoljak et al., 2016). Twenty-four hours before use, frozen porcine ears were 
thawed at 4°C, shaved and subcutaneous fat was removed with a scalpel. Microneedle patches were 
pressed for 3 sec, perpendicularly to the skin with a handmade, spring-loaded applicator, calibrated for 
10N. Patches were then withdrawn immediately from the skin or left in place for 1, 3, 5, 15, 30 and 60 
min after insertion in the skin, in the same manner as previously reported (Paleco et al., 2014; Vucen et 
al., 2013). Microneedles were assessed by microscopy before and after the applications in order to 
evaluate the needles dissolution kinetics. In all studies, the skin was subsequently stained with 
ShandonTM Blue Tissue Marker Dye (Thermo Fisher Scientific, USA) for 5 minutes. Excess dye was 
then removed with a swab wetted with PBS. The DMN-applied skin was excised and snap-frozen in 
O.C.T. medium. The frozen skin samples were cryo-sectioned into 10µm transverse sections, analyzed 
in bright field microscopy and subsequently stained with Trichome Masson’s stain. 
2.6 Immunogenicity and efficacy of LiHyp1 vaccines 
2.6.1 Animals and parasites
Female BALB/c mice, 4-6 weeks old (Envigo, UK) were used in the experiments for evaluation of the 
humoral and cellular immune response (n = 5 mice per group). These experiments were carried out in 
accordance with the European Directive 2010/63/EU, and under an authorization issued by the Health 
Products Regulatory Authority Ireland (license number AE19130/P030) and approved by the Animal 
Ethics Committee of University College Cork. For efficacy studies, female BALB/c mice (Élevages 
Janvier, Le Genest Saint Isle, France) aged 6-8 weeks and 18-20 g body weight were used (n ≥ 7 mice 
per batch). Vaccine efficacy studies were approved by the Committee Institutional Ethics for the 
Handling of Animals at the Université Paris-Sud (CEEA 26-063/2013). Leishmania donovani 
amastigotes (MHOM/ET/67/HU3 - also designated LV9) were obtained shortly after spleen isolation 
from previously infected Mesocricetus auratus (Golden Hamsters). Spleens were macerated in M199 
culture medium (Gibco®, Invitrogen, NY, USA), pH 7.0 supplemented with 0.1 mM adenosine, 5 μg/mL 
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hemin, 25 mM HEPES, 50 μg/mL penicillin and streptomycin (Sigma-Aldrich, St Louis, USA) 1%(v/v) 
inactivated FBS (Gibco®, Invitrogen, NY, USA).  The tissue homogenate was submitted to a series of 
centrifugations and lysis to release the amastigote from the infected cells, that were subsequently 
counted and adjusted to the concentration of 107 amastigotes/mL (Balaraman et al., 2015). 
2.6.2 Immunization protocol
BALB/c mice were immunized three times with 14-days intervals (days 0, 14, 28). Doses of each 
component were kept constant across all groups, i.e., 10 μg LiHyp1, 18 μg CpG and 250 μg lipids. For 
DMN patch administration, each patch consisted of 5 μg LiHyp1, 9 μg CpG and 125 μg lipids; 2 patches 
were administered to each animal. Five LiHyp1 vaccine groups were tested (n = 5 per group): (a) 
CL+CpG:SC; representing a control group consisting of the liquid LiHyp1 plus CpG liposomal 
formulation applied subcutaneously (SC) in 100 μL, (b) CL+CpG:DMN; LiHyp1 plus CpG in cationic 
liposomes in DMN, (c) CL:DMN; LiHyp1 in cationic liposomes in DMN (no CpG), (d) CpG:DMN; a non-
liposomal formulation of LiHyp1+CpG in DMN (no liposomes) and; (e) 100 μL of PBS injected 
subcutaneously. For each patch administration, the mice were pre-anesthetized with isoflurane and the 
patches were applied to the dorsal surface of each ear, pressing the fingers against the animals' skin 
for 10 sec, and left in place overnight. 
2.6.3 Immunogenicity evaluation
Mice were euthanized twelve days after the third immunization (day 40). Serum samples were stored at 
-20° C and spleens were homogenized and cryostored until use. Antibody responses to LiHyp1 were 
evaluated by ELISA, as previously described (Joyce et al., 2018).  Briefly, microtiter plates (MaxiSorp: 
Nunc) were coated with 2 μg/mL recombinant LiHyp1 in 1X carbonate buffer (0.1 M at pH 9.6).  Plates 
were incubated overnight at 4°C, then washed with PBS + 0.05% Tween 20 (PBST) and blocked with 
1% Bovine Serum Albumin (BSA) for 1 hr. Serum samples were serially diluted in 1% BSA solution and 
added to the coated plate.  After a 2-hr incubation, washed plates were incubated with goat anti-mouse 
IgG-HRP (1/10,000) or alternatively, anti IgG1-biotin or IgG2a-biotin. After a 1-hr incubation antigen-
specific antibodies were detected with 3,3’,5,5’-tetramethyl-Benzidine (TMB) substrate (BioLegend). 
Plates were then read at 655nm and titers were determined using endpoint titer method. Endpoint titers 
were taken as the x-axis intercept of the dilution curve at an absorbance value 3x standard deviations 
greater than the absorbance for naïve mouse serum.  For analysis of antigen-specific Th1/Th2 
induction, splenocytes were thawed and stimulated at 2 x 106 cells/ml in a total of 200 μL in 96-well 
culture plates (Costar, Corning, NY, USA) with LiHyp1 (1 μg/well) or Concanavalin A (ConA; 1 μg/well). 
Plates were incubated at 37°C, 5% CO2 for 48 h when culture supernatants were collected. Cytokine 
sandwich ELISA was performed to evaluate the production of IFN-γ and IL-10 using the reagents and 
specifications of the BD Kits OptEIA Mouse IFN-γ or IL-10 ELISA Set (BD, San Diego, CA, USA).
2.6.4 Vaccine efficacy
Twenty one days after the last immunization, BALB/c mice were challenged with infection of 
Leishmania donovani parasites with an inoculum of 1 x 106 amastigotes per mouse, intravenously by 
the ocular orbital plexus. Fifteen days after infection, animals were sacrificed, and the spleen and liver 
were individually collected. The organs were macerated in PBS in a 1:10 w/v and 200 μL from each 
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homogenate was added to lysis buffer plus proteinase K and incubated at 56°C overnight for complete 
tissue lysis. Genomic DNA (gDNA) was extracted from the samples with the illustra tissue and cells 
genomicPrep Mini Spin Kit’ (GE Healthcare®), following the manufacturer’s instructions and quantified 
by spectrophotometry using Tecan NanoQuant plate in Spark® Multimode Microplate Reader (Tecan, 
SWI). Real Time PCR (qPCR) was performed with a total amount of 50ng of gDNA of each sample, for 
quantification of Leishmania gDNA and determination of the parasite load in the organs and efficacy of 
vaccine protection. Primers used were: forward 5'-CCTATTTTACACCAACCCCCAGT-3 '[JW11], and 
reverse 5'-GGGTAGGGGCGTTC TGCGAAA-3' [JW12]), constructed for the amplification of a 120 bp 
specific region of minicircle present in Leishmania sp. kinetoplast DNA (kDNA) (Nicolas et al., 2002; 
Santi et al., 2018). gDNA from a known number of Leishmania donovani promastigotes was also 
extracted, dosed and serially diluted for construction of a standard curve from 5000 to 0.05 pg, 
corresponding to 500 to 0.5 parasites, according with the correlation: 1 leishmania parasite = 1 entire 
genomic DNA = 0.1 pg of gDNA weight (Manna et al., 2008; Marfurt et al., 2003). The determination of 
parasites of each normalized sample was made by interpolation of gDNA amplification Ct interpolated 
in linear regression graph of amplification Ct vs. leishmania gDNA weight in pg of the standard curve 
(Santi et al., 2018). 
2.7 Statistical analysis
Statistical analyses were performed in GraphPad Prism® 5.0 software using the Kruskal Wallis non-
parametric test and Dunns (or Mann Whitney) test for non-normal distribution data, and the one-way 
ANOVA with Bonferroni post-test (or Test t) for normal distribution data.
3 Results 
3.6 Characterization of purified LiHyp1 
In this work, the Leishmania infantum amastigote-specific protein LiHyp1 (XP_0014689 41.1) was 
expressed in Escherichia coli (C41 strain) and the recombinant antigen, fused with an N-terminal 6x 
histidine tag, was purified by FPLC (Fig. 1) and included in the vaccine formulations.  
Urea was present at high concentration (8 M) in rLiHyp1 purification buffer to promote protein 
solubilization, as rLiHyp1 is mostly present in insoluble bacteria extract (Coelho et al., 2012; Martins et 
al., 2013). We first determined the effect of urea concentration on antigen aggregation using DLS and 
confirmed by NTA, after dialysis into PBS or the DMN matrix formulation (trehalose 15% w/v + PVA 
1.25% w/v). It was observed rLiHyp1 forms aggregates in PBS at 8 M urea with average hydrodynamic 
diameter of 70.0 ± 8.3 nm (PDI = 0.20 ± 0.02) (Table 2). Reduction of urea concentration to 4 M 
resulted in increased particle mean diameter and polydispersity (diameter of 198.5 ± 7.6 nm with PDI = 
0.37 ± 0.01), suggesting an increase of rLiHyp1 aggregation (Table 2). Dialysis of rLiHyP1 in PBS at 
urea concentrations lower than 4 M caused rLiHyp1 precipitation in the dialysis cassette, suggesting 
super-aggregation. Dialysis of rLiHyp1 samples in DMN matrix formulation containing 0.8 M urea did 
not result in further protein aggregation or precipitation, as evidenced by the resulting homogenous 
colloidal solution with low PDI (0.17±0.02) and intermediate size, around 158.4±9.7(Table 2).
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2.6 Preparation and characterization of antigen in cationic liposomes (CL) and in DMN 
patches
The encapsulation of the antigenic protein in CL was performed according to the dehydration-
rehydration method (Zadi and Gregoriadis, 2000). We chose this process because it has been shown to 
preserve protein structure and allow high encapsulation rate. The use of trehalose as excipient has a 
double function: to control membrane fusion during the freeze-drying process and the final liposome 
size; to generate a matrix compatible with posterior incorporation into DMN that also contain trehalose 
as main component. Formulations of rLiHyp1 free (+ CpG) and rLiHyp1 liposomal (+ or - CpG) were 
prepared, dialyzed against DMN matrix at 0.8M urea and used to produce DMN patches. The 
macroscopic and biophysical features of the different rLiHyp1 formulations before and after the DMN 
manufacturing process are described in Table 2 and Fig. 2 .
To characterize the antigen-liposome formulation, firstly the rLiHyP1 encapsulation rate (ER) was 
assessed. Approximately 41% of rLiHyp1 added to CL remained associated to liposomes, while the 
addition of CpG to the formulation increased protein encapsulation up to 75% (Table 2). When rLiHyp1 
in liposomes (+/- CpG) were recovered from DMN, a reduced amount of antigen was found to be 
encapsulated compared to the starting material (Table 2; liposome encapsulated versus solid). 
Secondly, the particle size and morphology of the rLiHyp1 formulations were determined. Due to the 
high polydispersity index (PDI>0.5) of liposomal samples, measured by DLS, the particle diameter was 
determined by NTA. Liposome-encapsulated rLiHyp1 showed an average diameter around 200 nm and 
a positive zeta potential, with no significant change in these characteristics in the presence of CpG or 
after incorporation/dissolution of DMN (Table 2). One concern of formulating antigen-based liposomes 
into DMN patches was the integrity of the liposomes after dissolution of DMN. DLS, NTA size 
measurements and TEM images confirm that the vesicles could be recovered after DMN resuspension 
with similar size (~100-200nm) (Fig. 3). However, it is noteworthy that a higher polydispersity was 
observed in the liposome formulations after DMN incorporation and dissolution compared to the liquid 
formulation. In addition, TEM images of smaller, high contrasted aggregates outside or attached to the 
vesicle’s membrane, might represent rLiHyp1 aggregates, observed to be more numerous in the case 
of solution recovered from DMN. This may represent a concentration of rLiHyp1 aggregates outside of 
the vesicles, consistent with the significant reduction in the ER observed after insertion of liposomes 
into the DMN. Production of DMN patches was then assessed. The presence of urea (4M) in the CL, 
CpG and antigen formulation resulted in unacceptable microneedle formation, when BCG was used as 
antigen (Supplementary Table 1, Supplementary Figure 1). Thus urea was removed from all 
subsequent DMN formulations. The physical characteristics of the rLiHyp-1 microneedle patches were 
assessed. The DMN scores for all patches containing the 3 different rLiHyp-1 formulations were 
excellent (Table 2). The mechanical robustness of rLiHyp1 liposomal DMN were approximately 10N. 
(Table 2). Omission of the CL produced a DMN with substantially higher mechanical strength, an 
average pressure of 17.4 N/m2 was required to be applied before DMN compressed, compared to DMN 
that incorporated CL. This indicates that inclusion of cationic liposomes weakens the DMN patch. 
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Overall, these results demonstrated that the conditions to produce a liposomal LiHyp1 formulation 
incorporated into DMN produced patches of adequate physical characteristics of the microneedle and 
known physical stability of the liposomes in DMN. 
2.7 Skin penetration studies
We next sought to determine the capacity of DMN patches to penetrate skin. In this study, BSA was 
used in DMN patches as a surrogate antigen. DMN patches with soluble antigen or antigen 
incorporated into CL (+ or – CpG) were assessed for skin penetration and dissolution. After 
manufacture, 5 patches per batch of each DMN type, i.e., BSA in CpG:DMN, CL:DMN or 
CL+CpG:DMN , were examined for their ability to pierce cadaver porcine skin. A kinetic study of the 
DMN dissolution after application and removal from skin was performed to determine the minimum 
contact time for the patches that allowed a complete dissolution of DMN in the dermis. The insertion of 
the patches into the skin requires an estimated force of 10 N (McGrath et al., 2014). To ensure a 10 N 
force, a manual applicator with a force of 10 N was used to press the DMN patches into the skin for 3 
seconds. After this application patches were removed immediately or after 1, 5, 15, 30 and 60 minutes 
of contact with the skin, and analyzed by optical microscopy (Fig. 4).
All batches of DMN patches had similar dissolution kinetics and skin perforation pattern with no 
differences detected across the groups (data not shown). After 15 minutes of administration in the skin, 
microneedles were completely dissolved; no further dissolution or penetration occurred after this time 
(Fig. 4). To demonstrate skin perforation after DMN application, the site of administration was stained 
with methylene blue (Fig. 5B). Skin indentations were distinguished by the regular blue dots where the 
microneedles on the patch had penetrated the skin. Skin ruptures were observed (Fig. 5C and D). 
Stained images demonstrated that disruption made by the DMN go into the dermis, where there is a 
presence of collagen (stained in blue) (Fig. 5D).
2.8 Immunogenicity of vaccines in mice
The primary objective of the in vivo studies was to identify which vaccine in a DMN patch induced the 
highest protective immune response. The cellular and humoral immunogenicity of LiHyp1 in DMN 
patches, free or incorporated into liposomes, with or without CpG was evaluated and compared to a 
control vaccine regime of subcutaneous injection with liquid vaccine composed of rLiHyp1 incorporated 
into CL and with CpG.  Immunization with LiHyp1 and CpG and CL by the SC route, termed 
CL+CpG:SC, induced high IgG antibody titres (Fig. 6A), which were dominated by an IgG1 isotype 
(Fig. 6B, C, D). Immunization with rLiHyp1 + CpG, without liposomes, using DMN patches onto the skin 
(CpG:DMN) induced a total IgG response that was equivalent to the positive control vaccine given by 
the SC route. The antigen-specific IgG1 and IgG2a titers were not significantly different between the 
CpG:DMN and the liposome-based vaccine injected SC. Delivery of liposome-based vaccines using 
DMN into the skin, with or without CpG, termed CL+CpG:DMN and CL:DMN respectively, induced 
significantly lower IgG responses compared to the injected vaccine. Furthermore, low titers of IgG1 and 
IgG2a were observed in some mice immunized with these liposome-based DMN; these antibodies were 
undetectable in other mice in these groups (Fig 6B, C). Despite these low titers, there is a trend that the 
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addition of CpG to the liposome can skew the phenotype of the antibody isotype towards a stronger 
IgG2a response (Fig. 6D). However, addition of CpG had no effect on increasing the magnitude of the 
antibody response. These findings demonstrate that although the liposome-based vaccine is 
immunogenic when injected, its potency is significantly decreased when delivered by a DMN patch. 
However, the antigen, adjuvanted with CpG, is as immunogenic as an injected liposome vaccine when 
administered into the skin with a DMN patch. 
The Th1/Th2 phenotype of the response was also assessed in thawed spleen cell populations. The 
potential of thawed spleen cells to produce cytokines was assessed by responses to the mitogen, 
ConA. It can be seen that the cytokine-producing capacity of spleens from mice injected with the 
CL+CpG:SC and the CL+CpG:DMN were very low, suggesting that T cells were generally non-viable 
(Fig. 7). In contrast, spleens from the other two vaccinated groups responded well to ConA by 
producing IFN- and low levels of IL-10. It can be seen from these two responding groups 
(CL+CpG:DMN and CL:DMN) that addition of CpG to the liposome and administration using a DMN 
patch can increase the production of antigen-specific IFN- compared to skin administration of the 
antigen-encapsulated liposome alone, in some mice. Overall, little IL-10 was observed above the 
background level observed when spleen cells from naïve mice were stimulated with antigen. 
2.9 Protective efficacy of skin vaccination in mice
Vaccine efficacy was assessed by challenging immunized mice and naïve controls with Leishmania 
donovani amastigotes three weeks after the final immunization, Parasite load was assessed in liver and 
spleen. Significant protection against liver infection was induced in animals that were immunized with 
liposomes by the subcutaneous route (CL+CpG:SC) and when the antigen and CpG were administered 
into the skin using a DMN patch (CpG:DMN) (Fig. 8). Significantly decreased parasite load was also 
observed in the spleen but not in the liver when the antigen was encapsulated in liposomes, without 
CpG and delivered with a DMN patch (CL:DMN). Partial protection (50% parasite suppression in the 
liver and >90% in the spleen) due to the skin vaccination with the LiHyp1:CL:DMN formulation was 
observed. dno significant protection in either organ was induced by skin vaccination with the 
LiHyp1+CpG:CL:DMN vaccine. Thus, while the subcutaneous LiHyp1:CL+CpG vaccine confers an 
overall parasite suppression of 70%, the skin-based LiHyp1+CpG:DMN vaccine was the most effective 
one, with a protection rate > 90% in the two analyzed organs (Fig. 6). 
3 Discussion
Much has been done towards the development of a vaccine to prevent human leishmaniasis. 
Nevertheless, despite some first-generation formulations advancing to clinical trials, there is still no 
evidence of effective human protection against Leishmania infection (Gillespie et al., 2016), whereas 
some vaccines are already licensed for canine leishmaniasis. A human vaccine requires appropriate 
antigen and adjuvant delivery system and route of administration, so as to achieve high protection 
efficacy, safety, stability under storage and transport as well as low cost of production. Skin-based 
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vaccination systems containing second-generation antigen, nanoparticles and dissolvable microneedle 
patches, could provide efficient strategies to circumvent these problems. In the present work we 
designed an adjuvant system for rLiHyp1, a Leishmania amastigote-specific oxygenase recombinant 
protein, obtained by heterologous expression and purified in reasonable yield, based on cationic 
liposomes, with or without CpG and in dissolvable microneedles or by injection. We demonstrate that 
vaccination with a DMN patch incorporating the TLR9-adjuvanted antigen induced a high level of 
protective immunity mice against L. donovani infection. Our results indicate that this skin patch vaccine 
is as immunogenic and efficacious as an injected vaccine. In contrast, the immune response and 
efficacy was found to be eliminated when cationic liposomes were incorporated in the patch. To the 
best of our knowledge, this is the first report of induction of protective efficacy in experimental visceral 
leishmaniasis using a recombinant antigen-based dissolvable microneedle patch strategy. 
Immunoproteomic studies identified several immunogenic proteins in Leishmania infantum amastigote 
and promastigote extract, as well as their binding affinity to specific CD8+ and CD4+ T-cell epitopes, in 
order to obtain purified recombinant antigens to test as immunodiagnostics and vaccine candidates 
against leishmaniasis (Coelho et al., 2012; Duarte et al., 2016). Some of them, like LiHyp1, showed 
high protective efficacy when tested as a prophylactic vaccine in association with saponins in murine 
models of visceral leishmaniasis caused by L. infantum (Dias et al., 2018; Lage et al., 2015; Martins et 
al., 2015; Martins et al., 2016). Other single analogous or chimeric constructs of the protein showed 
cross-protection in murine challenging with L. amazonensis (Martins et al., 2017)) and L. infantum (Dias 
et al., 2018). Protective immunity against leishmaniasis is proposed to be related to induction of CD4+ 
and CD8+ T cells, with high levels of IFN-γ and low levels of IL-10 production and a balance of IgG2a to 
IgG1 (Stanley and Engwerda, 2007).  Adjuvants that induce a specific T helper 1 type immune 
response against the antigen are preferable for the development of a vaccine against leishmaniasis. 
Cationic liposomes, alone or in combination with immunostimulatory molecules, have been investigated 
to achieve safer and more effective adjuvant systems for entire or subunit antigens in vaccines against 
Leishmania and other infectious diseases. A previous study using a first generation, soluble Leishmania 
antigen (SLA) vaccine demonstrated significantly increased efficacy when the SLA was incorporated 
into CL with CpG and administered by the SC route (Heravi Shargh et al., 2012). We used a similar 
formulation to prepare vaccines against leishmaniasis containing rLiHyp1. However, in the present 
work, we demonstrate that these liposomes do not induce a protective immune response to Leishmania 
challenge when incorporated into DMN patches and administered into the skin.  
The immunity results demonstrate that further development of the rLiHyp1 in CL is required. The 
aggregation of rLiHyp1, resulted from reduction of urea concentration in the protein solution, has been 
a major issue in the development of some vaccine systems. The influence of protein aggregation level 
in immunogenicity is well studied in biotherapeutics (Moussa et al., 2016; Ratanji et al., 2014). Some 
studies have already shown that recombinant antigen aggregates are more immunogenic and 
protective than monomeric or oligomeric form, when combined with adjuvants (Ahmad et al., 2017; 
Qian et al., 2012). It is also appreciated that particulate antigen, such as hepatitis B surface antigen 
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particles or HPV virus like particles are highly immunogenic. In the case of rLiHyp1, protein aggregation 
has two important implications regarding the mechanism of antigen delivery. First, the nanoparticulate 
state of the protein may contribute to differential recognition and uptake by the immune cells of 
mononuclear phagocytic system, as proposed previously (Herrera Estrada and Champion, 2015). This 
may contribute to the protective efficacy of the DMN patch incorporating the TLR9-adjuvanted antigen 
and the liquid vaccine containing aggregated antigen with CL and CpG. Secondly, part of the rLiHyp1 
protein that is present in the CL formulation maybe self-aggregated separately from the lipid vesicles 
containing the antigen, as suggested by DLS, NTA and TEM images showing highly contrasted 
nanoparticles outside or attached to the vesicle surface. Thus, rLiHyp1 protein probably exists under 
three different states in the CL liposome formulation: physically encapsulated in the internal aqueous 
compartment of liposomes; adsorbed onto the liposome surface due to electrostatic interactions; and 
self-aggregated outside the liposomes. Since the encapsulation rate of liposomes was measured by 
centrifugation, we presume that large nanoaggregates (>150nm) of free antigen could sediment 
together with the liposomes and be counted as entrapped protein. In this context, the reduced 
concentration of protein in the centrifuged pellet after incorporation of CL into DMN could be due to a 
decrease of encapsulated rLiHyp1 during the DMN drying process and resuspension or to a 
stabilization of protein nanoaggregates in a smaller size, that remained in the supernatant during the 
centrifugation process. This antigen was potent when injected with CL and CpG or when incorporated 
with CpG in DMN patches. 
Another interesting observation was that the rLiHyp1 encapsulation rate increased with the addition of 
CpG to the formulation. While some authors observed no influence of CpG co-encapsulation on the 
protein entrapment in cationic liposomes (Badiee et al., 2008), others observed the contrary, i.e. a 
decrease in the encapsulation efficiency when soluble proteins and CpG ODN are co-encapsulated in 
cationic liposomes (Bal et al., 2011). DNA-based molecules are known for inducing fusion in cationic 
liposomes, due to electrostatic interactions and ability to form DNA-cationic lipid complexes, such with 
DOTAP (Mok and Cullis, 1997). In this work, we propose that the binding of CpG ODN to the cationic 
membrane may have favored vesicle fusion, leading to an increase in the rLiHyp1 encapsulation into 
the liposomes.
DMNs containing antigen and CpG only had good mechanical robustness, however inclusion of CL 
weakened the DMN. The lower immunogenicity of the liposomal-DMN in comparison with 
rLiHyp1+CpG:DMN and the rLiHyp1+CpG:CL:SC could indicate non-optimal skin insertion for those 
formulations, likely related to weak DMN mechanical robustness (observed failure force of 9 N/m2 
compared to 17 N/m2 for non-liposomal DMN), resulting in lower vaccine bioavailability. rLiHyp1-specific 
IgG levels produced in mice immunized by the mechanically stronger DMN, (non-liposomal, 
rLiHyp1+CpG), were higher compared to those generated by liposomal DMN formulations. This 
suggests issues in antigen and/or adjuvant bioavailability and consequently antigen recognition, uptake 
and presentation may be responsible for poor immunogenicity of the CL-DMN systems. A previous 
study, which examined transcutaneous administration of cationic liposomes charged with CpG and 
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ovalbumin, showed that the CL significantly decreased the antigen / CpG uptake by dendritic cells due 
to an extra transport step across the epidermis, although in vitro DC stimulation showed a higher 
potential of this formulation (Slutter et al., 2011).  This suggests that the presence of CL in the DMN 
could also have impacted antigen uptake due to preferable antigen retention in the epidermis. If true, 
then this suggests that cationic liposomes are unsuitable as adjuvants for vaccines delivered 
transcutaneously. The weakness conferred by the lipids in our DMN differs from other studies. These 
studies  suggested that  very weak liposomal DMN, (bent when a force of 4N was applied)  pierced the 
skin when applied with a force superior to 2N (Qiu et al., 2016). Other studies, did not report the DMN 
mechanical robustness, but have reported the capacity to induce immune responses (Guo et al., 2013). 
These DMN formulations are often prepared with a higher concentration of polymer (usually > 20% 
w/w, PVP) in comparison with 1.25% w/w of PVA contained in the formulations developed in this work. 
Additionally, some DMN formulations that were stated to be immunogenic (Guo et al., 2013) were 
fabricated based on the antigen being concentrated to the DMN tip, which may increase antigen 
bioavailability. Therefore, future studies should address the lack of immunogenicity with our CL DMN, 
possibly due to low biodistribution, by using previously described formulations and microneedle designs 
(Marshall et al., 2016). These results encourage, overall, the optimization and improvement of the 
development of CL+CpG:DMN formulations in order to increase DMN mechanical strength and vaccine 
bioavailability and consequently improve the protection potential of this formulation.
Skin vaccination using microneedle patches skews the antibody isotype towards a dominant IgG1, Th2-
type antibody response; this has been observed across several microneedle systems (Pulit-Penaloza et 
al., 2014; Weldon et al., 2012). Although liposomal rLiHyp1-DMN patches induced weak humoral 
immune responses, when compared to non-liposomal DMN patch,  the skin vaccination of mice with 
rLiHyp1+CpG:CL was the only one that appeared to shift the balance of IgG subtypes towards IgG2a, 
in some animals of this group. This fact was reinforced by a higher IFN-γ cytokine secreted by LiHyP1 
stimulated splenocytes from the animals in the same group compared to all others. Unfortunately, 
methodological problems prevented a statistical comparison of T cell data, as a lot of splenocyte 
samples were not responsive to in vitro cytokine stimulation. Furhter studies are required to determine if 
the development of a CL-containing DMN patch is worthwhile  with respect to modulating the immune 
response toward a Th1 response.
For L. donovani infection in the liver, the rLiHyp1+CpG:DMN vaccine induced the greatest protection 
among all groups, similar to subcutaneous injection of rLiHyp1+CpG:LC, whereas the liposomal DMN 
system was not able to induce a significant reduction in the parasite load compared to unvaccinated 
mice.  The protective efficacy of the liposomal-based DMN may also have been compromised by the 
suboptimal mechanical strength of these patches and decreased antigen bioavailability. Although both 
the SC injected vaccine and the CpG:DMN vaccines induced significantly reduced parasite load in the 
spleen, only the DMN patches induced the highest reduction in parasite load also in the liver, compared 
to naïve animals. This indicates that skin-based vaccination, using microneedles, with the rLiHyp1 
antigen and CpG adjuvant is beneficial.
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Based on the particle size characterization of this vaccine system, it is likely that some of the LiHyp1 
antigen had aggregated into a homogenous particulate suspension of acceptable PDI (Table 2). This 
suggests that the particulate antigen maybe beneficial to the vaccine effect. Here we suggest that 
adjuvanted antigen aggregates delivered into the skin are immunogenic and induce protection against 
parasite infection. It will be important in future studies to assess the quaternary structure of this 
recombinant antigen as well as the relative importance of the route and method of immunization by 
determining if this antigen and CpG vaccine can induce similar efficacy if it is injected.
There are significant advantages of the microneedle patch compared to injection-based immunization 
of liquid vaccine, with respect to the elimination of biohazardous needles, syringes and the need for 
cold chain, Thus, from a logistics perspective, development of a stable, easy-to-administer leishmania 
vaccine patch is highly desirable. Our results demonstrate that this patch-based leishmania vaccine 
induces highly protective immune responses. This provides a foundation for further development and 
optimization of this technology for eventual clinical deployment.  
4 Conclusions
The results of this work prove that a skin vaccine system comprised of a rLiHyp1 associated with CpG 
(DMN LiHyp1 + CpG) in dissolvable microneedle patches induces excellent levels of protective 
immunity in mice against experimental leishmaniasis challenge. This system has a high potential for 
minimally invasive vaccination against leishmaniasis, presenting a promising skin-based possibility for 
the prevention of the disease. Secondly, this work demonstrates that dissolvable microneedle patches 
incorporating cationic liposomes and parasite antigens can be produced, with and without CpG. 
However, these patches should be further developed to improve the homogeneity of the formulation 
and the mechanical robustness of the microneedle. If future studies demonstrate the advantages of 
enhanced vaccine stability then this system presents a potential to reduce costs involved in the vaccine 
manufacturing, storage and application. The possibility of greater adherence by patients to an easy-to-
administer vaccine format, should increase the success in vaccination programmes. In conclusion, the 
microneedle patch skin vaccine format proposed here represent a potential vaccine technology for the 
prevention of leishmaniasis that has promise for further development and translation to humans.
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Figure Legends 
Figure 1. Heterologous expression and purification of Leishmania recombinant protein LiHyp1. 
(A) LiHyp1 DNA sequence, cloned in plasmid, transfected in Escherichia coli and purified by FPLC. 
LiHyp1 3D protein model obtained using SWISS-Model Repository. (B) SDS-PAGE and (C) Western 
blot of the purified fractions, using anti-His tag antibody was performed to confirm purity and specificity 
of rLiHyp1. 
Figure 2. Dissolvable microneedles patches. (A)  PDMS (polydimethylsiloxane) mold for 
manufacturing of dissolvable microneedles (McGrath et al., 2014). (B) Macroscopic aspect of a patch 
(left) and an individual microneedle (right) prepared from a CL + LiHyp1 + CpG obtained through a light 
microscope, inverted, with a magnification of 20 times. (C) Images of rLiHyp1-liposomal DMN in lower 
magnitude (left) and zoomed (right) from scanning electron microscopy (SEM).
Figure 3. Size and morphology of rLiHyp1 liposomes, before and after incorporation in DMN. 
Size distribution (diameter, nm) of CL containing rLiHyp1 and CpG measured by NTA, (A) before or (B) 
after incorporation into DMN. TEM images (PTA 1% contrast agent) of CL containing rLiHyp1 (C) 
before and (D) after insertion in DMN; scale bar = 200nm.
Figure 4. Kinetics of DMN patch dissolution in skin. Figures represent DMN containing BSA and 
CpG incorporated into CL before and after application into pig skin. The time intervals evaluated were 
immediately after insertion or 1, 3, 5 and 15 minutes after application and maintenance. The DMN were 
applied with the aid of a manual applicator, calibrated with the force of 10N, perpendicular to the axial 
axis of the DMN.
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Figure 5. Study of DMN insertion into porcine skin. (A) Scheme of DMN porcine skin application. 
Images of: (B) en face image of skin after DMN application and immediate withdrawal, with subsequent 
indentation staining by methylene blue stain; Bright field photomicrography of pig-skin cryosections 
mounted on glass slide with Entelan®. Breach made by a DMN into the skin as imaged by (C) 
brightfield and (D) subsequent to Trichome-Masson staining.  Normal skin as imaged by (E) brightfield 
and (F) subsequent to Trichome-Masson staining. Magnification 400X, scale bar = 20μm. The arrow 
indicates where it is possible to identify a typical DMN penetration event.
Figure 6. Antibody responses induced by LiHyp1 containing vaccines.  BALB/c female mice were 
immunized on days 0, 14 and 28 with LiHyp1 encapsulated with CpG in cationic liposomes and 
administered by the SC route “(LiHyp1+CpG)CL SC” or with DMN patches containing LiHyp1 and CpG 
encapsulated in cationic liposomes; “(LiHyp1+CpG)CL DMN”, or with LiHyp1 encapsulated in cationic 
liposomes; “(LiHyp1)CL DMN” or with LiHyp1 and CpG incorporated into DMN patches without 
liposomes;  “LiHyp1 +CpG DMN”.  Serum was assessed for LiHyp1-specific IgG (A), IgG1 (B), or IgG2a 
(C) on day 40.  (D) Ratio of IgG2a endpoint titers to IgG1 titers in each animal. Bars represent median 
values with interquartile range. Symbols represent individual animals.  *; p < 0.05; ** p < 0.01, 
significantly different to the other vaccinated groups at 8 weeks, using Kruskal-Wallis one-way ANOVA. 
The dotted line represents the initial serum dilution of 1/100.
Figure 7. T cell responses induced by LiHyp1 containing vaccines. IFN-γ (A) or IL-10 (B) produced 
by thawed spleen cells stimulated with 1µg LiHyp1 (dark bars) or with ConA (light bars) for 48 hours. 
BALB/c female mice were immunized as described in Figure 6. The horizontal dashed line in (B) 
represents the maximum background level of IL-10 produced by naïve cells stimulated with LiHyp1.
Figure 8. Protective immunity conferred by LiHyp1 vaccines in DNM patches in skin or in CL for 
subcutaneous injection, in a BALB/c - L. donovani murine model of visceral leishmaniasis. 
BALB/c mice were first immunized, as described in Figure 6 legend or a group were injected (SC) with 
PBS. All mice were infected with 1 x 106 L. donovani amastigotes 3 weeks after the last immunization. 
Parasite load was determined by qPCR absolute quantification. Statistical analysis was performed with 
the Kruskal-Wallis test followed by the Dunns test in relation to the PBS control, *p <0.01; **p <0.001, 
***p<0,0001. The results are shown as median and interquartile range. N ≥ 7 per group.
Supplementary Figure 1. Macroscopic aspect of DMN prepared from a CL + BSA + CpG at (A) 4M 
of urea and (B) 0.8M of urea. The images were obtained with a light microscope, inverted, with a 
magnification of 20 times.
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Table 1. DMN 4-tier scoring system
Score DMN Description Scheme
4
‘Perfect DMN’: 8 sided DMN, sharp tips
Table 1 - DMN 4- e c e
Score DMN description Scheme
4 Pe fec DMN : 8 ded DMN, a
3
Nea Pe fec DMN : 6-4 sided DMN or cone shaped,
or wizard hat or blunt tip
2 V ca e ,
1 Stub/no DMN
3
‘Near Perfect DMN’: 6-4 sided DMN or 
cone shaped or wizard hat or blunt tip
Table 1 - DMN 4- e c e
Score DMN description Scheme
4 Pe fec DMN : 8 ded DMN, a
3
Nea Pe fec DMN : 6-4 sided DMN or cone shaped,
or wizard hat or blunt tip
2 V ca e ,
1 Stub/no
2
‘Volcano type’, no tip
Table 1 - DMN 4- e c e
Score DMN description Scheme
4 P fec DMN : 8 ded DMN, a
3
Nea Pe fec DMN : 6-4 sided DMN or cone shaped,
or wizard hat or blunt tip
2 V ca e ,
1 Stub/no DMN
1 Stub/no DMN
Table 1 - DMN 4- e c e
Score DMN description Scheme
4 Pe fec DMN : 8 ded DMN, a
3
Nea Pe fec DMN : 6-4 sided DMN or cone shaped,
or wizard hat or blunt tip
2 V ca e ,
1 Stub/no DMN
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Table 2- Biophysical characteristics of LiHyp1 formulations
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NA 17.4 98 
1LiHyp1 in PBS solution containing 4 M urea was prepared by dialysis of the 
initial purified LiHyp1 in PBS/8 M urea. 2LiHyp1 initial purified solution was 
dialyzed into the DMN formulation, trehalose 15% (w/v) + PVA 1.25% (w/v) 
containing 0.8M of urea, in order to equilibrate the solutes’ concentration. 
3Liposome-encapsulated samples were diluted (100x) in PBS (size) or water 
(zeta potential) before DLS and NTA measurements. 4Each DMN patch was 
dissolved in 1 mL of PBS before NTA and DLS measurements. CL: cationic 
liposome; Mean size (d.nm): average of results of particle size measurements 
by NTA technique. SD: standard deviation. PDI: polydispersity index given by 
DLS technique. Zeta P.: Zeta potential in millivolts (mV), measured by DLS. 
ER: Encapsulation rate in percentage. Pressure is given in Newtons per 
square meter (N/m2); The DMN were scored based on DMN ‘4-tier’ scoring 
system – Table 1
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